We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBRA icon
301
Sabra Healthcare REIT
SBRA
$5.56B
$444K 0.01%
23,848
-2,812
-11% -$47.4K
INO icon
302
Inovio Pharmaceuticals
INO
$85.6M
$442K 0.01%
+76,523
New +$631K
KNSL icon
303
Kinsale Capital Group
KNSL
$8.58B
$440K 0.01%
+945
New +$418K
CI icon
304
Cigna
CI
$78.4B
$437K 0.01%
1,260
+523
+71% +$180K
CRL icon
305
Charles River Laboratories
CRL
$11.3B
$434K 0.01%
+2,204
New +$458K
CXM icon
306
Sprinklr
CXM
$1.51B
$431K 0.01%
+55,785
New +$491K
NNN icon
307
NNN REIT
NNN
$9.29B
$431K 0.01%
+8,891
New +$411K
TKO icon
308
TKO Group
TKO
$14B
$430K 0.01%
+3,472
New +$397K
LNC icon
309
Lincoln National
LNC
$7.92B
$428K 0.01%
+13,586
New +$424K
ACIC icon
310
American Coastal Insurance
ACIC
$536M
$426K 0.01%
+37,834
New +$423K
CRGX
311
DELISTED
CARGO Therapeutics
CRGX
$426K 0.01%
+23,078
New +$413K
CVBF icon
312
CVB Financial
CVBF
$4.02B
$424K 0.01%
+23,802
New +$425K
USFD icon
313
US Foods
USFD
$22.5B
$421K 0.01%
+6,845
New +$383K
RUN icon
314
Sunrun
RUN
$2.26B
$421K 0.01%
+23,300
New +$414K
COO icon
315
Cooper Companies
COO
$14.2B
$410K 0.01%
3,716
-12,893
-78% -$1.25M
VCYT icon
316
Veracyte
VCYT
$4.45B
$410K 0.01%
+12,032
New +$338K
WM icon
317
Waste Management
WM
$95B
$406K 0.01%
+1,958
New +$408K
NWN icon
318
Northwest Natural Holdings
NWN
$2.15B
$406K 0.01%
+9,940
New +$388K
DVA icon
319
DaVita
DVA
$15.5B
$405K 0.01%
+2,472
New +$365K
AMSF icon
320
AMERISAFE
AMSF
$562M
$400K 0.01%
+8,283
New +$394K
GS icon
321
Goldman Sachs
GS
$289B
$400K 0.01%
+808
New +$395K
NVST icon
322
Envista
NVST
$4.62B
$399K 0.01%
+20,167
New +$351K
OLMA icon
323
Olema Pharmaceuticals
OLMA
$977M
$398K 0.01%
33,296
+1,891
+6% +$24.2K
SVC
324
Service Properties Trust
SVC
$1.05B
$397K 0.01%
17,427
+11,778
+208% +$293K
FF icon
325
Future Fuel
FF
$205M
$396K 0.01%
+68,916
New +$383K
11 12
13
14 15

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.